Every Form 4 that Genprex Inc (GNPX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GNPX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GNPX filings page.
Genprex, Inc. director Brent M. Longnecker reported small open-market sales of Genprex common stock, primarily for tax purposes. On April 14, 2026, he sold 8 shares of common stock at $1.23 per share from his direct holdings and 10 shares at $1.23 per share through indirect ownership by Longnecker Associates Ltd. Following these transactions, he directly holds 9,157 shares of Genprex common stock, with no remaining indirect shares reported in this filing.
Genprex, Inc.’s Chief Medical Officer, Mark Stanley Berger, reported a tax-related share withholding. On February 27, 2026, 7,168 shares of common stock were withheld to cover tax obligations tied to the vesting of Restricted Stock Units granted under Genprex’s 2018 Equity Incentive Plan. After this tax-withholding disposition, he directly owned 21,692 shares of Genprex common stock.
Genprex, Inc. director and executive officer Ryan M. Confer reported a Form 4 transaction showing a tax-withholding disposition of 9,330 shares of common stock at $2.00 per share. According to the disclosure, these shares were withheld on February 27, 2026 to satisfy tax withholding obligations tied to vesting restricted stock units granted under the company’s 2018 Equity Incentive Plan. After this withholding, Confer directly holds 36,331 shares of Genprex common stock.
Genprex, Inc. reported that its Chief Medical Officer received an award of 28,500 restricted stock units (RSUs) of common stock on 12/22/2025. The RSUs were granted at a price of $0 per share under the company’s 2018 Equity Incentive Plan, as amended and restated effective June 30, 2025.
The award vests in two equal installments of 50% on February 27, 2026 and 50% on February 27, 2027, conditioned on continued service through each vesting date. Once vested, each RSU will be settled in one share of Genprex common stock. After this grant and giving effect to a 1-for-50 reverse stock split of Genprex’s common stock that was effective as of October 21, 2025, the reporting officer beneficially owns 28,860 shares of common stock.
Genprex, Inc. reported that its President, CEO and CFO, Ryan Confer, received an award of 45,000 restricted stock units (RSUs) of common stock on December 22, 2025 under the company’s 2018 Equity Incentive Plan. These RSUs vest in two equal installments of 50% on February 27, 2026 and 50% on February 27, 2027, if he continues to serve as a service provider through each vesting date. Each vested RSU will be settled in one share of Genprex common stock. Following this grant and giving effect to Genprex’s 1-for-50 reverse stock split effective as of October 21, 2025, Confer beneficially owns 45,661 shares of Genprex common stock in total.
Genprex, Inc. director Brent Longnecker reported receiving an award of 9,000 Restricted Stock Units (RSUs) of Genprex common stock on 12/22/2025 under the company’s 2018 Equity Incentive Plan. These RSUs vest 100% on the earlier of August 15, 2026 or the day before Genprex’s next annual stockholder meeting after the grant date, as long as he continues to serve as a service provider through that date. Each vested RSU will be settled in one share of Genprex common stock.
After this grant and giving effect to Genprex’s 1-for-50 reverse stock split effective as of October 21, 2025, Longnecker beneficially owns 9,165 shares of common stock directly and 10 shares indirectly through Longnecker Associates Ltd.